Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc (ACAD) Straddle
ACAD straddle scan found 88 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 71.7%.
Read more
Trading a ACAD straddle lets you take a pure volatility position on Acadia Pharmaceuticals Inc without committing to a direction. Acadia Pharmaceuticals Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate ACAD straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on ACAD profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Acadia Pharmaceuticals Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the ACAD straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's.
ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the ACAD straddle is the cleanest expression of that view. Our scanner prices every ACAD straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a ACAD straddle into a catalyst or short a ACAD straddle to harvest decay, the options straddle setups that matter are all in one place.
| Mar 19, 2027 | 37.00 | $13.78 | 183 | 100% | 71.7% | $50.78 | $23.23 | 0 |
| Mar 19, 2027 | 36.00 | $13.23 | 183 | 100% | 71.6% | $49.23 | $22.78 | 2 |
| Mar 19, 2027 | 34.00 | $12.28 | 183 | 100% | 71.1% | $46.28 | $21.73 | 0 |
| Mar 19, 2027 | 35.00 | $12.98 | 183 | 100% | 70.8% | $47.98 | $22.03 | 0 |
| Mar 19, 2027 | 33.00 | $12.00 | 183 | 100% | 70.4% | $45.00 | $21.00 | 0 |
| Mar 19, 2027 | 32.00 | $11.78 | 183 | 100% | 69.4% | $43.78 | $20.23 | 0 |
| Mar 19, 2027 | 31.00 | $11.28 | 183 | 100% | 69.3% | $42.28 | $19.73 | 1 |
| Jan 15, 2027 | 37.00 | $12.68 | 120 | 100% | 68.3% | $49.68 | $24.33 | 0 |
| Mar 19, 2027 | 30.00 | $11.10 | 183 | 100% | 68.2% | $41.10 | $18.90 | 0 |
| Mar 19, 2027 | 29.00 | $10.68 | 183 | 100% | 67.9% | $39.68 | $18.33 | 0 |
As of September 18, 2026
Find the right straddle before volatility moves
Track ACAD straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→